VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

Amgen Inc. vs ChemoMetec A/S

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Amgen Inc.

AMGN · Nasdaq Stock Market

Market cap (USD)$187.9B
Gross margin (TTM)70.5%
Operating margin (TTM)28%
Net margin (TTM)21%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2025-12-22
Moat score
70/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Amgen Inc.'s moat claims, evidence, and risks.

View AMGN analysis

ChemoMetec A/S

CHEMM · Nasdaq Copenhagen A/S

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryDK
Data as of2026-04-24
Moat score
67/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into ChemoMetec A/S's moat claims, evidence, and risks.

View CHEMM analysis

Comparison highlights

  • Moat score gap: Amgen Inc. leads (70 / 100 vs 67 / 100 for ChemoMetec A/S).
  • Segment focus: Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines); ChemoMetec A/S has 2 segments (94.8% in Life science research, cell and gene therapy, and bioprocessing).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Moderate.
  • Moat breadth: Amgen Inc. has 5 moat types across 3 domains; ChemoMetec A/S has 4 across 2.

Primary market context

Amgen Inc.

Core Innovative Medicines

Market

Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)

Geography

Global

Customer

Payers, providers, and pharmacies

Role

Drug developer/manufacturer

Revenue share

80.1%

ChemoMetec A/S

Life science research, cell and gene therapy, and bioprocessing

Market

Global cell counting and analysis instruments for LCB workflows

Geography

Global, skewed to USA/Canada and Europe

Customer

Pharmaceutical, biotech, cell and gene therapy, bioprocessing, and research labs

Role

OEM instrument, consumables, software, and service provider

Revenue share

94.8%

Side-by-side metrics

Amgen Inc.
ChemoMetec A/S
Ticker / Exchange
AMGN - Nasdaq Stock Market
CHEMM - Nasdaq Copenhagen A/S
Market cap (USD)
$187.9B
n/a
Gross margin (TTM)
70.5%
n/a
Operating margin (TTM)
28%
n/a
Net margin (TTM)
21%
n/a
Sector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
n/a
HQ country
US
DK
Primary segment
Core Innovative Medicines
Life science research, cell and gene therapy, and bioprocessing
Market structure
Competitive
Oligopoly
Market share
n/a
15%-25% (estimated)
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
70 / 100
67 / 100
Moat domains
Legal, Supply, Demand
Demand, Network
Last update
2025-12-22
2026-04-24

Moat coverage

Shared moat types

Brand Trust

Amgen Inc. strengths

IP Choke PointRegulated Standards PipeCapex Knowhow ScaleLearning Curve Yield

ChemoMetec A/S strengths

Installed Base ConsumablesDesign In QualificationInteroperability Hub

Segment mix

Amgen Inc. segments

Full profile >

Core Innovative Medicines

Competitive

80.1%

Rare Disease Portfolio (Horizon + others)

Quasi-Monopoly

13.3%

Biosimilars

Oligopoly

6.6%

ChemoMetec A/S segments

Full profile >

Life science research, cell and gene therapy, and bioprocessing

Oligopoly

94.8%

Production control and quality control of animal semen, beer and milk

Quasi-Monopoly

5.2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.